Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India

Citations Over TimeTop 10% of 2017 papers

Abstract

Setting: India has one of the highest global rates of multidrug-resistant tuberculosis (MDR-TB), which is associated with poor treatment outcomes. A better understanding of the risk factors for unfavourable outcomes is needed. Objectives: To describe 1) the demographic and clinical characteristics of MDR-TB patients registered in three states of India during 2009-2011, 2) treatment outcomes, and 3) factors associated with unfavourable outcomes. Design: A retrospective cohort study involving a record review of registered MDR-TB patients. Results: Of 788 patients, 68% were male, 70% were aged 15-44 years, 90% had failed previous anti-tuberculosis treatment or were retreatment smear-positive, 60% had a body mass index 2 and 72% had additional resistance to streptomycin and/or ethambutol. The median time from sputum collection to the start of MDR-TB treatment was 128 days (IQR 103-173). Unfavourable outcomes occurred in 40% of the patients, mostly from death or loss to follow-up. Factors significantly associated with unfavourable outcomes included male sex, age ⩾ 45 years, being underweight and infection with the human immunodeficiency virus. Adverse drug reactions were reported in 24% of patients, with gastrointestinal disturbance, psychiatric morbidity and ototoxicity the most common. Conclusion: Long delays from sputum collection to treatment initiation using conventional methods, along with poor treatment outcomes, suggest the need to scale up rapid diagnostic tests and shorter regimens for MDR-TB.

Related Papers

• → Lack of Correlation betweenembBMutation and Ethambutol MIC inMycobacterium tuberculosisClinical Isolates from China(2007)21 cited
• Simultaneous ethambutol & isoniazid resistance in clinical isolates of Mycobacterium tuberculosis.(2006)
• → Extensively drug-resistant tuberculosis: a case report and literature review(2008)9 cited
• Rates of ophthalmic complications due to ethambutol in patients with non-tuberculous mycobacteria(2012)
• Surveillance on first-line anti-tuberculosis drug resistance at Shanghai Port(2012)